Zachariah Holmes, PhD

Zachariah Holmes is an Associate in Goodwin’s Intellectual Property Litigation practice. Zachariah contributes to the firm’s work in patent and trade secret litigation, patent opinions and due diligence, and commercial disputes with a concentration in the areas of biotechnology and pharmaceuticals.

Zachariah has been involved in various stages of patent litigation, including discovery, pretrial proceedings, and a federal jury trial. Some of his engagements include:

• Amyndas Pharmaceuticals Single Member P.C. et al. v. Alexion Pharmaceuticals, Inc. et al., C.A. No. 20-12254-LTS (D. Mass.). Representing Zealand Pharma A/S and Zealand Pharma U.S. Inc. in a trade secret litigation related to peptide therapeutics
• Teva Pharmaceuticals International GmbH et al. v. Eli Lilly and Company, C.A. No. 18-12029-ADB (D. Mass.). Represented Teva in asserting method of treatment patents regarding anti-CGRP antibodies against Eli Lilly’s Emgality® (galcanezumab) product
• Certain Pre-Filled Syringes for Intravitreal Injection and Components Thereof, Inv. No. 337-TA-1207 (USITC); Novartis Pharma AG et al v. Regeneron Pharmaceuticals, Inc., C.A. No. 20-00690-DNH (N.D.N.Y.); Regeneron Pharmaceuticals, Inc. v. Novartis Pharma AG, et al., IPR2020-01317, IPR2020-01318, IPR2021-00816 (P.T.A.B.). Represented Novartis in ITC investigation and related litigations and inter partes review proceedings concerning assertion of Novartis’s pre-filled syringe patent against Regeneron’s EYLEA® (aflibercept) product
• Par Pharmaceutical et al. v. Amneal et al., C.A. No. 18-2032-CFC (D. Del.). Represented Amneal Pharmaceuticals in patent infringement case involving a generic formulation of Vasostrict® (vasopressin) injection
• Various non-public representations, including confidential arbitration proceedings involving pharmaceutical IP licensing disputes

Zachariah joined Goodwin in 2019 as a Science Advisor and subsequently attended Suffolk University Law School as a part-time student. Prior to joining Goodwin, Zachariah obtained his PhD in Biochemistry from the University of Colorado, where he used a number of biophysical approaches to characterize the properties of a protein that regulates pluripotency in embryonic stem cells. Zachariah’s research experience also includes the characterization of an improved RNA-based live-cell imaging technique and the investigation of several RNA-based mechanisms of gene regulation.

Zachariah is a member of the Massachusetts LGBTQ Bar Association.

Zachariah was awarded the Leo J. Wyman Award by the faculty of Suffolk University Law School as well as the Rehnquist Award for Excellence in Professional Responsibility.

Zachariah has published scientific articles in peer-reviewed journals, including Nature Chemical Biology, Nature Communications and Nucleic Acids Research. He is an editor of Big Molecule Watch, Goodwin’s blog covering legal, business and regulatory developments involving biologics, biosimilars and the Biologics Price Competition and Innovation Act (BPCIA).

• Contributor, “Guide to Biosimilars Litigation and Regulation in the U.S., 2023-2024 ed.,” Thomson Reuters, January 2024
• Contributor, “Guide to Biosimilars Litigation and Regulation in the U.S., 2019-2020 ed.,” Thomson Reuters, November 2019